|Over a week ago|
HealthEquity appoints Tyson Murdock as deputy CFO, to succeed CFO Darcy Mott » 08:1706/2606/26/20
HealthEquity announced that Tyson Murdock has been appointed EVP and Deputy CFO, effective July 1, 2020, and will succeed Darcy Mott as CFO April 1, 2021. Mr. Mott will continue in his current position as EVP and CFO through March 31, 2021 to ensure a smooth transition and completion of the fiscal year 2021 Form 10-K filing for the Company and will then transition into an advisory role to the CEO. Murdock joined HealthEquity in 2018 as SVP and Corporate Controller and brings 25 years of corporate finance experience to his new role as CFO.
|Over a month ago|
HealthEquity earnings selloff a buying opportunity, says Barrington » 09:5106/0306/03/20
Barrington analyst Alexander Paris recommends using today's post-earnings selloff in shares of HealthEquity as a buying opportunity. The quarter was mixed as revenue was slightly below and adjusted EBITDA was slightly above expectations, and guidance for fiscal 2021 was withdrawn given the uncertainty related to COVID-19, Paris tells investors in a research note. The pandemic has impacted HealthEquity's results more than originally thought, but the company's financial performance should improve as the economy gradually begins to reopen, says the analyst. Paris reiterates an Outperform rating on HealthEquity with a $65 price target.
HealthEquity price target lowered to $70 from $80 at Cantor Fitzgerald » 07:2706/0306/03/20
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Steven Halper lowered the firm's price target on HealthEquity to $70 from $80 and keeps an Overweight rating on the shares following the company's quarterly results, saying the company began to feel the negative effects of COVID-19 in March. While the near-term outlook appears soft, Halper believes that the company should be well-positioned beyond COVID and remains confident that HealthEquity should continue to gain market share despite the uncertain environment.
Fly Intel: After-Hours Movers » 19:1006/0206/02/20
APPS, CRWD, MCHP, CAKE, AVID, LYFT, HQY, AMBA, ZM, MDLA, RGA, EVFM, GLUU
Check out this evening's…
HealthEquity withdraws FY21 guidance amid COVID-19 pandemic » 16:0806/0206/02/20
Said Kessler, "We…
Said Kessler, "We believe the COVID-19 pandemic's negative effect on our operating performance will fade as businesses gradually reopen, while the unprecedented economic fallout drives HSA growth and accelerates long-term trends favoring established market leaders like HealthEquity."
HealthEquity sees Q2 EPS 23c-30c, consensus 45c » 16:0806/0206/02/20
Sees Q2 revenue…
Sees Q2 revenue $168M-$173M, consensus $191.45M
HealthEquity reports Q1 EPS 43c, consensus 44c » 16:0406/0206/02/20
Reports Q1 revenue…
Reports Q1 revenue $190.01M, consensus $193.32M."The team's remarkable response to the COVID-19 pandemic has strengthened HealthEquity's culture and accelerated promised synergies," said Jon Kessler, president and CEO. "During a tumultuous quarter, 17% year-over-year increase in new HSA openings and 33% Adjusted EBITDA margin show just how deeply growth and profitability are embedded in our model."
Notable companies reporting after market close » 14:1906/0206/02/20
ZM, CRWD, HQY, MDLA, AMBA
Notable companies reporting after the market close, with earnings consensus, include Zoom Video (ZM), consensus 9c... CrowdStrike (CRWD), consensus (6c)... HealthEquity (HQY), consensus 44c... Medallia (MDLA), consensus (2c)... Ambarella (AMBA), consensus (1c).
Guggenheim starts HealthEquity at Buy with $56 price target » 09:0404/1404/14/20
As previously reported,…
As previously reported, Guggenheim analyst Vikram Kesavabhotia initiated coverage of HealthEquity with a Buy rating and $56 price target. While he appreciates the significant concerns around COVID-19 and the interest rate environment, Kesavabhotia sees HealthEquity being well positioned to capture continued HSA industry growth with a more comprehensive go-to-market strategy following its WageWorks deal. He sees an attractive risk/reward following the company's revised F21 guidance and pullback in the shares, along with a variety of potential growth drivers for upside.
HealthEquity initiated with a Buy at Guggenheim » 06:5104/1404/14/20
Guggenheim analyst Vikram…
Guggenheim analyst Vikram Kesavabhotia initiated coverage of HealthEquity with a Buy rating and $56 price target.